<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02693041</url>
  </required_header>
  <id_info>
    <org_study_id>Dnr. 929-11</org_study_id>
    <nct_id>NCT02693041</nct_id>
  </id_info>
  <brief_title>Pregnancy Complications - A Probiotic Interventional Study</brief_title>
  <official_title>Pregnancy Complications - A Probiotic Interventional Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sahlgrenska University Hospital, Sweden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators hypothesize that&#xD;
&#xD;
      a) probiotics decrease the overall inflammatory state in the pregnant woman, especially in&#xD;
      women with high risk pregnancies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main of the Project is to determine if dietary supplementation intake of probiotics are&#xD;
      associated with a decreased inflammatory response in pregnant women, especially those with a&#xD;
      history of previous preterm birth or preeclampsia, in a randomized clinical trial.&#xD;
      Investigators also want to further investigate the relationship between intake of probiotics&#xD;
      and the degree of inflammation in different compartments during pregnancy to see how the&#xD;
      probiotic components affect the inflammatory state in the women.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 2012</start_date>
  <completion_date type="Anticipated">September 27, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 27, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Inflammatory modulation of Lactobacillus Rhamnosus in low risk mothers.</measure>
    <time_frame>at recruitment, week 25, week 35 of gestation</time_frame>
    <description>Intake of LGG Rhamnosus throughout the pregnancy and its effect on levels of subpopulations of lymphocytes in peripheral blood (T/B/NK-celler), and cytokine production (TNF alfa, IL10, IL12) after stimulation with E. Coli, L. paracasei and P. aerugnousa, measuring change from baseline to 25 and 35 weeks gestation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory modulation of Lactobacillus Rhamnosus in mothers with previous preterm birth.</measure>
    <time_frame>at recruitment, week 25, week 35 of gestation</time_frame>
    <description>Intake of LGG Rhamnosus throughout the pregnancy and its effect on levels of subpopulations of lymphocytes in peripheral blood (T/B/NK-celler), and cytokine production (TNF alfa, IL10, IL12) after stimulation with E. Coli, L. paracasei and P. aerugnousa, measuring change from baseline to 25 and 35 weeks gestation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory modulation of Lactobacillus Rhamnosus in mothers with previous preeclampsia.</measure>
    <time_frame>at recruitment, week 25, week 35 of gestation</time_frame>
    <description>Intake of LGG Rhamnosus throughout the pregnancy and its effect on levels of subpopulations of lymphocytes in peripheral blood (T/B/NK-celler), and cytokine production (TNF alfa, IL10, IL12) after stimulation with E. Coli, L. paracasei and P. aerugnousa, measuring change from baseline to 25 and 35 weeks gestation.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Preeclampsia</condition>
  <condition>Preterm Birth</condition>
  <arm_group>
    <arm_group_label>PROBIOTIC in low-risk women</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In low-risk women, probiotic group will be treated with the Active ingredient containing Lactobacillus rhamnosus (LGG) (&gt; 10x8 CFU) during all pregnancy until delivery. Capsules contain maltodextrin, LGG and vegetal magnesium stearate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLACEBO in low-risk women</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In low-risk women, placebo group will be treated with the placebo ingredient during all pregnancy until delivery. The capsules of the placebo Group have similar content but lack the probiotic lactic acid bacteria which has been replaced by maltodextrin to make the mg amount equal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PROBIOTIC in women with a prior PTB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In women with a prior preterm birth (PTB), probiotic Group will be treated with the Active ingredient containing Lactobacillus rhamnosus (LGG) (&gt; 10x8 CFU) during all pregnancy until delivery. Capsules contain maltodextrin, LGG and vegetal magnesium stearate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLACEBO in women with a prior PTB</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In women with a prior preterm birth (PTB), placebo group will be treated with the placebo ingredient during all pregnancy until delivery. The capsules of the placebo Group have similar content but lack the probiotic lactic acid bacteria which has been replaced by maltodextrin to make the mg amount equal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PROBIOTIC in women with a prior PE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In women with a prior preeclampsia (PE), probiotic Group will be treated with the Active ingredient containing Lactobacillus rhamnosus (LGG) (&gt; 10x8 CFU) during all pregnancy until delivery. Capsules contain maltodextrin, LGG and vegetal magnesium stearate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLACEBO in women with a prior PE</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In women with a prior preeclampsia (PE), placebo Group will be treated with the placebo ingredient during all pregnancy until delivery. The capsules of the placebo Group have similar content but lack the probiotic lactic acid bacteria which has been replaced by maltodextrin to make the mg amount equal.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>probiotic</intervention_name>
    <description>Low-risk women, women with prior preeclampsia and women with a prior preterm birth will be randomized to be treated with LGG during pregnancy. Effect on maternal and perinatal outcome as well as the effect of treatment on immunological and inflammatory biomarkers will be evaluated.</description>
    <arm_group_label>PROBIOTIC in low-risk women</arm_group_label>
    <arm_group_label>PROBIOTIC in women with a prior PE</arm_group_label>
    <arm_group_label>PROBIOTIC in women with a prior PTB</arm_group_label>
    <other_name>Lactobacillus rhamnosus</other_name>
    <other_name>LGG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Low-risk women, women with prior preeclampsia and women with a prior preterm birth will be randomized to be treated with placebo during pregnancy. Effect on maternal and perinatal outcome as well as the effect of treatment on immunological and inflammatory biomarkers will be evaluated.</description>
    <arm_group_label>PLACEBO in low-risk women</arm_group_label>
    <arm_group_label>PLACEBO in women with a prior PE</arm_group_label>
    <arm_group_label>PLACEBO in women with a prior PTB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Maternal age &gt; or = 18 y&#xD;
&#xD;
          -  Singleton pregnancy&#xD;
&#xD;
          -  Nulli or multiparous without maternal intercurrent diseases or pregnant women with a&#xD;
             history of spontaneous preterm delivery or pregnant women with a history of&#xD;
             preeclampsia.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Multiple pregnancy&#xD;
&#xD;
          -  Gestational age &gt; 17+6 weeks at first visit&#xD;
&#xD;
          -  Chronic intermittent diseases (e.g. diabetes mellitus, systemic lupus erythematosus,&#xD;
             rheumatoid arthritis, Chron disease, ulcerative colitis)&#xD;
&#xD;
          -  Uterus malformations&#xD;
&#xD;
          -  Immunomodulatory medication&#xD;
&#xD;
          -  Hormonal treatment (e.g. crinone, progesterone)&#xD;
&#xD;
          -  Subject disagrees to stop intake of other products containing probiotics during study&#xD;
             time.&#xD;
&#xD;
          -  Subject is unable to provide written informed consent&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bo Jacobsson, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Göteborg University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bo Jacobsson</name>
      <address>
        <city>Gothenburg</city>
        <zip>416 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <results_reference>
    <citation>Aagaard K, Ma J, Antony KM, Ganu R, Petrosino J, Versalovic J. The placenta harbors a unique microbiome. Sci Transl Med. 2014 May 21;6(237):237ra65. doi: 10.1126/scitranslmed.3008599.</citation>
    <PMID>24848255</PMID>
  </results_reference>
  <results_reference>
    <citation>Cobo T, Kacerovsky M, Palacio M, Hornychova H, Hougaard DM, Skogstrand K, Jacobsson B. Intra-amniotic inflammatory response in subgroups of women with preterm prelabor rupture of the membranes. PLoS One. 2012;7(8):e43677. doi: 10.1371/journal.pone.0043677. Epub 2012 Aug 20.</citation>
    <PMID>22916296</PMID>
  </results_reference>
  <results_reference>
    <citation>Gonçalves LF, Chaiworapongsa T, Romero R. Intrauterine infection and prematurity. Ment Retard Dev Disabil Res Rev. 2002;8(1):3-13. Review.</citation>
    <PMID>11921380</PMID>
  </results_reference>
  <results_reference>
    <citation>Jiménez E, Fernández L, Marín ML, Martín R, Odriozola JM, Nueno-Palop C, Narbad A, Olivares M, Xaus J, Rodríguez JM. Isolation of commensal bacteria from umbilical cord blood of healthy neonates born by cesarean section. Curr Microbiol. 2005 Oct;51(4):270-4. Epub 2005 Sep 20.</citation>
    <PMID>16187156</PMID>
  </results_reference>
  <results_reference>
    <citation>Jiménez E, Marín ML, Martín R, Odriozola JM, Olivares M, Xaus J, Fernández L, Rodríguez JM. Is meconium from healthy newborns actually sterile? Res Microbiol. 2008 Apr;159(3):187-93. doi: 10.1016/j.resmic.2007.12.007. Epub 2008 Jan 11.</citation>
    <PMID>18281199</PMID>
  </results_reference>
  <results_reference>
    <citation>Myhre R, Brantsæter AL, Myking S, Gjessing HK, Sengpiel V, Meltzer HM, Haugen M, Jacobsson B. Intake of probiotic food and risk of spontaneous preterm delivery. Am J Clin Nutr. 2011 Jan;93(1):151-7. doi: 10.3945/ajcn.110.004085. Epub 2010 Oct 27.</citation>
    <PMID>20980489</PMID>
  </results_reference>
  <results_reference>
    <citation>Brantsaeter AL, Myhre R, Haugen M, Myking S, Sengpiel V, Magnus P, Jacobsson B, Meltzer HM. Intake of probiotic food and risk of preeclampsia in primiparous women: the Norwegian Mother and Child Cohort Study. Am J Epidemiol. 2011 Oct 1;174(7):807-15. doi: 10.1093/aje/kwr168. Epub 2011 Aug 5.</citation>
    <PMID>21821542</PMID>
  </results_reference>
  <results_reference>
    <citation>Bertelsen RJ, Brantsæter AL, Magnus MC, Haugen M, Myhre R, Jacobsson B, Longnecker MP, Meltzer HM, London SJ. Probiotic milk consumption in pregnancy and infancy and subsequent childhood allergic diseases. J Allergy Clin Immunol. 2014 Jan;133(1):165-71.e1-8. doi: 10.1016/j.jaci.2013.07.032. Epub 2013 Sep 10.</citation>
    <PMID>24034345</PMID>
  </results_reference>
  <results_reference>
    <citation>Yeganegi M, Watson CS, Martins A, Kim SO, Reid G, Challis JR, Bocking AD. Effect of Lactobacillus rhamnosus GR-1 supernatant and fetal sex on lipopolysaccharide-induced cytokine and prostaglandin-regulating enzymes in human placental trophoblast cells: implications for treatment of bacterial vaginosis and prevention of preterm labor. Am J Obstet Gynecol. 2009 May;200(5):532.e1-8. doi: 10.1016/j.ajog.2008.12.032. Epub 2009 Mar 14.</citation>
    <PMID>19285652</PMID>
  </results_reference>
  <results_reference>
    <citation>Yeganegi M, Leung CG, Martins A, Kim SO, Reid G, Challis JR, Bocking AD. Lactobacillus rhamnosus GR-1 stimulates colony-stimulating factor 3 (granulocyte) (CSF3) output in placental trophoblast cells in a fetal sex-dependent manner. Biol Reprod. 2011 Jan;84(1):18-25. doi: 10.1095/biolreprod.110.085167. Epub 2010 Sep 1.</citation>
    <PMID>20811016</PMID>
  </results_reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>October 12, 2015</study_first_submitted>
  <study_first_submitted_qc>February 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2016</study_first_posted>
  <last_update_submitted>May 12, 2021</last_update_submitted>
  <last_update_submitted_qc>May 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sahlgrenska University Hospital, Sweden</investigator_affiliation>
    <investigator_full_name>Bo Jacobsson</investigator_full_name>
    <investigator_title>Clinical professor</investigator_title>
  </responsible_party>
  <keyword>Probiotics</keyword>
  <keyword>inflammation</keyword>
  <keyword>immunological response</keyword>
  <keyword>preterm birth</keyword>
  <keyword>preeclampsia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>Pregnancy Complications</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 1, 2011</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/41/NCT02693041/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

